Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/16/20 → 9/5/23 |
Funding
- Syneos Health LLC: $655,261.00
A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY-1
- Villano, PhD, John (PI)
- Chauhan, Aman (Former PI)